---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-230774"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2026-05-19T20:13:42+00:00"
generated_at: "2026-05-19T21:24:50.095407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Iridex Q1 revenue $11.8M (-1% YoY); net loss narrows to $0.5M; Cyclo G6 up 14%

## Summary
- Revenue $11.8M, down 1% YoY; Cyclo G6 product revenue $3.6M (+14% YoY) on 15,500 probes sold.
- Net loss $0.5M ($0.03/sh) compared to $1.7M ($0.10/sh) in Q1 2025; Non-GAAP adjusted EBITDA $0.3M.
- Gross margin 40% vs 43% a year ago, pressured by tariffs and transition to low-cost manufacturers.
- Cash $4.6M; company expects positive cash flow for full year 2026 despite typical Q1 usage.
- FY2026 revenue guidance reaffirmed at $51M-$53M; adjusted opex guided $19M-$19.5M.

## SEC filing metadata
- accession: 0001193125-26-230774
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2026-05-19T20:13:42+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/0001193125-26-230774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/irix-20260519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-230774
- JSON: https://secwatch.observer/filing/0001193125-26-230774.json
- Plain text: https://secwatch.observer/filing/0001193125-26-230774.txt

## Key facts
- Earnings Releases
  IRIDEX CORP reported first quarter ended April 4, 2026 results: revenue $11.8 million, net income $0.5 million or $0.03 per share, EPS $0.03 per share. Guidance reaffirmed.
  - Period: first quarter ended April 4, 2026
  - Revenue: $11.8 million
  - Net income: $0.5 million or $0.03 per share
  - EPS: $0.03 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights • Generated total revenue of $11.8 million, compared to $11.9 million in the prior year period • Cyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/0001193125-26-230774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.